Alzheimer's disease and melatonin

Etsuro Matsubara; Mikio Shoji; Tetsuro Murakami; Takeshi Kawarabayashi; Koji Abe

doi:10.1016/S0531-5131(03)00019-0

Alzheimer's disease and melatonin

Etsuro Matsubara, Mikio Shoji, Tetsuro Murakami, Takeshi Kawarabayashi, Koji Abe

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.

Original language	English
Pages (from-to)	395-398
Number of pages	4
Journal	International Congress Series
Volume	1252
Issue number	C
DOIs	https://doi.org/10.1016/S0531-5131(03)00019-0
Publication status	Published - Jun 1 2003
Externally published	Yes

Keywords

Alzheimer's disease
Amyloid β
Anti-amyloidogenic properties of melatonin
Antioxidant properties of melatonin
Melatonin

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0531-5131(03)00019-0

Cite this

@article{9b287ef6d1ed40e2ae9143ac7cd6f295,

title = "Alzheimer's disease and melatonin",

abstract = "Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.",

keywords = "Alzheimer's disease, Amyloid β, Anti-amyloidogenic properties of melatonin, Antioxidant properties of melatonin, Melatonin",

author = "Etsuro Matsubara and Mikio Shoji and Tetsuro Murakami and Takeshi Kawarabayashi and Koji Abe",

year = "2003",

month = jun,

day = "1",

doi = "10.1016/S0531-5131(03)00019-0",

language = "English",

volume = "1252",

pages = "395--398",

journal = "International Congress Series",

issn = "0531-5131",

publisher = "Elsevier BV",

number = "C",

}

TY - JOUR

T1 - Alzheimer's disease and melatonin

AU - Matsubara, Etsuro

AU - Shoji, Mikio

AU - Murakami, Tetsuro

AU - Kawarabayashi, Takeshi

AU - Abe, Koji

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.

AB - Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.

KW - Alzheimer's disease

KW - Amyloid β

KW - Anti-amyloidogenic properties of melatonin

KW - Antioxidant properties of melatonin

KW - Melatonin

UR - http://www.scopus.com/inward/record.url?scp=4644249295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644249295&partnerID=8YFLogxK

U2 - 10.1016/S0531-5131(03)00019-0

DO - 10.1016/S0531-5131(03)00019-0

M3 - Article

AN - SCOPUS:4644249295

VL - 1252

SP - 395

EP - 398

JO - International Congress Series

JF - International Congress Series

SN - 0531-5131

IS - C

ER -

Alzheimer's disease and melatonin

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this